Anti-Interleukin-31 (IL-31)

Interleukin-31 (IL-31) is a recently discovered T-cell cytokine closely related to IL-6 type cytokines and is preferentially produced by T helper type 2 cells (1,2). IL- 31 activity is mediated through the ligand-induced oligomerization of a dimeric receptor complex containing IL-31 receptor A and oncostatin M receptor (2). In response to IL-31 binding, these proteins activate the JAK/STAT and the AKT signaling pathways (3). RNA levels of IL-31 receptor A and oncostatin M receptor are induced in activated monocytes but are expressed constitutively in epithelial cells (1). IL-31, when overexpressed in transgenic mice, results in the development of pruritis, alopecia, and skin lesions and in humans may result in atopic dermatitis, suggesting that IL- 31 may represent a novel target for antipruritic drug development (1,4). , Applications: Suitable for use in Western Blot. Other applications not tested. Recommended Dilution: Western Blot: 2.5-5ug/ml, ~27-30kD, Optimal dilutions to be determined by the researcher. Positive Control: Human skeletal muscle lysate, Storage and Stability: May be stored at 4°C for short-term only. For long-term storage and to avoid repeated freezing and thawing, add sterile glycerol (40-50%), aliquot and store at -20°C. Aliquots are stable for at least 12 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.